HLS Therapeutics Inc HLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CAD 4.65
- Day Range
- CAD 4.65–4.65
- 52-Week Range
- CAD 3.34–7.12
- Bid/Ask
- CAD 3.50 / CAD 4.75
- Market Cap
- CAD 148.27 Mil
- Volume/Avg
- 14 / 10,289
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.76
- Dividend Yield (Trailing)
- 1.08%
- Dividend Yield (Forward)
- —
- Total Yield
- 2.49%
Company Profile
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 90
- Website
- https://www.hlstherapeutics.com
Comparables
Valuation
|
Metric
|
HLS
|
SCLX
|
000640
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 20.19 |
Price/Book Value | 1.15 | — | 0.68 |
Price/Sales | 1.76 | 2.35 | 0.61 |
Price/Cash Flow | 10.33 | — | 5.04 |
Price/Earnings
HLS
SCLX
000640
Financial Strength
|
Metric
|
HLS
|
SCLX
|
000640
|
|---|---|---|---|
Quick Ratio | 1.22 | 0.15 | 0.44 |
Current Ratio | 1.65 | 0.19 | 0.66 |
Interest Coverage | −2.22 | −106.04 | 3.70 |
Quick Ratio
HLS
SCLX
000640
Profitability
|
Metric
|
HLS
|
SCLX
|
000640
|
|---|---|---|---|
Return on Assets (Normalized) | −7.18% | −106.47% | 3.28% |
Return on Equity (Normalized) | −14.58% | — | 6.15% |
Return on Invested Capital (Normalized) | −3.86% | −1,960.39% | 4.65% |
Return on Assets
HLS
SCLX
000640
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Pzmjrrnvm | Kcwq | $72.8 Bil | |
MKKGY
| Merck KGaA ADR | Gykrchhyr | Hshwhw | $69.4 Bil | |
HLN
| Haleon PLC ADR | Mvszsph | Gdq | $38.9 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Sdzsvdvnn | Rrxm | $15.9 Bil | |
VTRS
| Viatris Inc | Zwbmkxnj | Yhghc | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qzmbrvsnm | Ptht | $12.4 Bil | |
CTLT
| Catalent Inc | Lklysjfc | Gcsrckp | $10.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Qbqjpljv | Brdg | $4.6 Bil | |
PRGO
| Perrigo Co PLC | Pjgslhgg | Wwlw | $4.4 Bil | |
GTBIF
| Green Thumb Industries Inc | Kckzshjtk | Nyv | $3.7 Bil |